ALL_10108 XEN folder mars 2020

Identifying patients suitable for XEN Identifying patients suitable for XEN

Promotional and educational material produced and funded by Allergan Date of preparation: February 2020 ND-XEN-2050002

r t i c n e r easo c t n e i n t s a s n P o i t ra

Pa tie nt

Patients exhibiting any of the following characteristics may be deemed suitable for XEN:

d e ne

Where previous treatments have failed:

1. Difficulty or reluctance to adhere to number of drops1 2. Interested in a procedure combining cataract surgery with additional IOP lowering1 3. Anxious about more invasive surgical options2

1. Sub-optimally controlled on drops • Not at target IOP3 • Not achieving a 20-30% IOP reduction4 2. Non-adherent to their drops regimen4,5

L O

e d i s n co

3. Intolerant of drops5

Me d i c a t i o n &

Q

XEN is suited to first line glaucoma surgery (POAG) when drops aren’t enough or previous medical treatments have failed 5,12

Ma nif es tp

2.

Structural progression – RNFL, inner macula and/or optic disc rim thinning7,8

1. Long life expectancy 9 2. High baseline IOP9 4. VFI deterioration of ≥1%/year6 5. VF close to fixation11

Ris k o f

3. VF damage ~7 dB at baseline10

se centric reaso n sea s Di

n sio es gr ro

1.

Functional progression - VFI deterioration of ≥1%/year6

p r o g r e s s

n io

lity abi dis or

1. Reitsamer H et al. Graefes Arch Clin Exp Ophthalmol 2019; 257(5): 98396. 2. Vera V et al. US Ophthalmic Rev 2018; 11(1): 38-46. 3. Leske ME et al.

Arch Ophthalmol 2003; 121: 48-56. 4. European Glaucoma Society (EGS).

Terminology and guidelines for glaucoma. 4th edition. 2014. 5. Allergan XEN directions for use. 2016. 6. Leung CKS et al. Ophthalmology 2011; 118: 1551-7. 7. Miki A et al. J Curr Glaucoma Pract 2012; 6(2): 62-7. 8. Ohnell H et al.

Ophthalmology 2016; 123(6): 1173-80. 9. Ernest PJ et al. Ophthalmology 2013; 120(3): 512-9. 10. Chauhan BC et al. Invest Ophthalmol Vis Sci 2014; 55(7): 4135-43. 11. Membrey WL et al. Br J Ophthalmol 2000; 84(10): 1154-8.

12. Manasses DT and Au L. Ophthalmol Ther 2016; 5(2): 135-46.

XEN is a medical device class III CE 0086. XEN is licensed for the reduction of intraocular pressure in patients with primary open angle glaucoma where previous medical treatments have failed. Always refer to full instructions before use. XEN is not commercially available in all countries. License terms and registration may vary by country. Please contact your local Allergan office for a list of countries where XEN is available.

Adverse events should be reported to your local regulatory office and your Allergan office.